Ilaina Monroe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ilaina Monroe has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Muhammed Kashif Riaz
University of Cincinnati 1 Cincinnati, OH
112 shared publications - Trisha Michel Wise-Draper
Division of Hematology/Oncology, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio
112 shared publications - Nicky Kurtzweil
University of Cincinnati Cancer Center, Cincinnati, Ohio
102 shared publications - Nusrat Harun
Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
102 shared publications - Maria Lehn
University of Cincinnati 1 Cincinnati, OH
99 shared publications - McKenzie Crist
University of Cincinnati 1 Cincinnati, OH
99 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Data from A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer
Purpose:Survival for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) remains low with <20% immunotherapy response. Metformin increases tumor-infiltrating CD8+ T and natural killer (NK) cells, which harbor PD-1. In this phase II clinical trial (NCT04414540), we combined metformin and pembrolizumab to evaluate the overall response rate (ORR) in R/M HNSCC and assess NK-cell activity. Patients and Methods:Eligible patients were randomized 1:1 into two arms: (i) metformin extended-release (ER) dose escalation to 2,000 mg over 14 days followed by combination with pembrolizumab 200 mg every 3 weeks or (ii) pembrolizumab 200 mg every 3 weeks followed by combination with metformin ER 2,000 mg daily. The primary endpoint was ORR per RECIST 1.1. Nineteen evaluable patients were planned to estimate the proportion of approximately 32% ORR. Safety was evaluated according to Common Terminology Criteria for Adverse Events v5.0. The distribution, activation, and cytotoxic function of NK cells were analyzed via flow cytometry. Results:Twenty-one patients were enrolled; 76% were male, 52% were smokers, and the median age was 64 years. Ten patients had oropharyngeal tumors, of which nine were p16+. Eighteen patients were evaluable for response, including four complete and five partial responses for an ORR of 50% [95% confidence interval (29–71)]. Combination therapy was well tolerated with no unexpected adverse events (AE). Five grade 3 AEs occurred: nausea, diarrhea, fatigue, and weight loss. Metformin led to increased peripheral NK-cell maturation and cytotoxic ability. Conclusions:The combination of metformin and pembrolizumab was well tolerated with mild gastrointestinal AEs and promising activity, warranting further investigation in a randomized trial.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer
Purpose:Survival for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) remains low with <20% immunotherapy response. Metformin increases tumor-infiltrating CD8+ T and natural killer (NK) cells, which harbor PD-1. In this phase II clinical trial (NCT04414540), we combined metformin and pembrolizumab to evaluate the overall response rate (ORR) in R/M HNSCC and assess NK-cell activity. Patients and Methods:Eligible patients were randomized 1:1 into two arms: (i) metformin extended-release (ER) dose escalation to 2,000 mg over 14 days followed by combination with pembrolizumab 200 mg every 3 weeks or (ii) pembrolizumab 200 mg every 3 weeks followed by combination with metformin ER 2,000 mg daily. The primary endpoint was ORR per RECIST 1.1. Nineteen evaluable patients were planned to estimate the proportion of approximately 32% ORR. Safety was evaluated according to Common Terminology Criteria for Adverse Events v5.0. The distribution, activation, and cytotoxic function of NK cells were analyzed via flow cytometry. Results:Twenty-one patients were enrolled; 76% were male, 52% were smokers, and the median age was 64 years. Ten patients had oropharyngeal tumors, of which nine were p16+. Eighteen patients were evaluable for response, including four complete and five partial responses for an ORR of 50% [95% confidence interval (29–71)]. Combination therapy was well tolerated with no unexpected adverse events (AE). Five grade 3 AEs occurred: nausea, diarrhea, fatigue, and weight loss. Metformin led to increased peripheral NK-cell maturation and cytotoxic ability. Conclusions:The combination of metformin and pembrolizumab was well tolerated with mild gastrointestinal AEs and promising activity, warranting further investigation in a randomized trial.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer
Figure S1 from A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer
Figure S1 from A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer
Figure S2 from A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer
Figure S2 from A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer
Figure S3 from A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer
Figure S3 from A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer
Figure S4 from A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer
Figure S4 from A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer
Figure S5 from A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer
Figure S5 from A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer
Supplemental Tables and fig legends
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer
Supplemental Tables and fig legends
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer
Figure S7 from A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer
Figure S7 from A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer
Figure S6 from A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer
Figure S6 from A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer
- 25 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (18) , 4016-4025
A Phase 2 Feasibility Study Combining Pembrolizumab and Metformin in patients with Metastatic Head and Neck Cancer
Background: Survival for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) remains low with <20% immunotherapy response. Metformin increases tumor-infiltrating CD8+ T and natural killer (NK) cells, which harbor PD-1. In this Phase 2 clinical trial (NCT04414540), we combined metformin and pembrolizumab to evaluate the overall response rate (ORR) in R/M HNSCC and assess NK cell activity. Methods: Eligible patients were randomized 1:1 into two arms: (1) metformin ER dose escalation to 2000 mg over 14 days followed by combination with pembrolizumab 200 mg q3 weeks or (2) pembrolizumab 200 mg q3 weeks followed by combination with metformin ER 2000 mg daily. The primary endpoint was ORR per RECIST 1.1. Nineteen evaluable patients were planned to estimate the proportion of approximately 32% ORR. Safety was evaluated by CTCAE v5.0. The distribution, activation, and cytotoxic function of NK cells was analyzed by flow cytometry. Results: Twenty-one patients were enrolled. 76% were male, 52% smokers, and median age was 64. Ten patients had oropharyngeal tumors, of which 9 were p16 positive. Eighteen patients were evaluable for response, including 4 complete and 5 partial responses for an ORR of 50% (95%CI [29,71]). Combination therapy was well tolerated with no unexpected adverse events (AEs). Five Grade 3 AEs occurred, including nausea, diarrhea, fatigue, and weight loss. Metformin led to increased peripheral NK cell maturation and cytotoxic ability. Conclusion: The combination of metformin and pembrolizumab was well tolerated with mild GI-associated AEs and promising activity warranting further investigation in a randomized trial.
- 25 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (18) , 4016-4025
A Phase 2 Feasibility Study Combining Pembrolizumab and Metformin in patients with Metastatic Head and Neck Cancer
Background: Survival for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) remains low with <20% immunotherapy response. Metformin increases tumor-infiltrating CD8+ T and natural killer (NK) cells, which harbor PD-1. In this Phase 2 clinical trial (NCT04414540), we combined metformin and pembrolizumab to evaluate the overall response rate (ORR) in R/M HNSCC and assess NK cell activity. Methods: Eligible patients were randomized 1:1 into two arms: (1) metformin ER dose escalation to 2000 mg over 14 days followed by combination with pembrolizumab 200 mg q3 weeks or (2) pembrolizumab 200 mg q3 weeks followed by combination with metformin ER 2000 mg daily. The primary endpoint was ORR per RECIST 1.1. Nineteen evaluable patients were planned to estimate the proportion of approximately 32% ORR. Safety was evaluated by CTCAE v5.0. The distribution, activation, and cytotoxic function of NK cells was analyzed by flow cytometry. Results: Twenty-one patients were enrolled. 76% were male, 52% smokers, and median age was 64. Ten patients had oropharyngeal tumors, of which 9 were p16 positive. Eighteen patients were evaluable for response, including 4 complete and 5 partial responses for an ORR of 50% (95%CI [29,71]). Combination therapy was well tolerated with no unexpected adverse events (AEs). Five Grade 3 AEs occurred, including nausea, diarrhea, fatigue, and weight loss. Metformin led to increased peripheral NK cell maturation and cytotoxic ability. Conclusion: The combination of metformin and pembrolizumab was well tolerated with mild GI-associated AEs and promising activity warranting further investigation in a randomized trial.